The Prague-based biotechnological start-up Elphogene has received an initial investment from i&i Prague in order to implement its oncoMonitor™, a liquid biopsy technology into a commercial assay for non-invasive diagnostic monitoring of patients in advanced stages colorectal cancer.
The company has been founded at the beginning of 2019 as a spin-off from the Genomac Research Institute.
Results & Experiences
We have been investigating ctDNA from patients' blood since 2009. We gained experience with patients with various types of cancer (lungs, pancreas, stomach, head and neck), but we found out the best application for colorectal cancer patients for whom oncoMonitor™ was primarily developed.
So far, in several extensive research studies, we have examined more than 500 such patients for the presence of ctDNA, and in at least 30 of them, we conducted long-term postoperative monitoring of ctDNA levels.
News & Media
Scientists from Elphogene and the Genomac Research Institute in collaboration with leading oncology centers from the Czech Republic have published an article in an international scientific journal.
Marek Minarik, Ph.D. presented the company Elphogene in Prague, Czech Republic.
Marek Minarik, Ph.D. presented the company Elphogene in Brno, Czech Republic.
Marek Minarik, Ph.D. presented the company Elphogene in Pilsen, Czech Republic.
Czech scientists present a unique technology to detect the relapse of colorectal cancer, which can prolong patients’ lives.
Vynález českých vědců odhalí, jestli se pacientům vrací rakovina. Stačí odebrat krev.
Čeští vědci vyvíjejí metodu, která odhalí návrat rakoviny z pouhých několika kapek krve.
Čeští vědci přišli na to, jak analýzou krve pomoci onkologickým pacientům.
Čeští vědci vyvinuli nové testy na rakovinu.